Chemistry Capability / Capacity Development Analytical Track

提高能力和能力 微生物和化学测试，以支持 综合食品防御和食品安全系统 化学学科，能力/能力发展分析跟踪 项目概要/摘要 俄亥俄州农业部（ODA）消费者保护实验室（CPL）建议 将FDA开发的过敏原筛选方法纳入他们的实验室， 人类食品的常规筛选方法。xMAP食品过敏原检测试剂盒 (xMAP FADA）试剂盒通过多重检测技术进行创新， 常规ELISA技术;优点包括能够测试多种过敏原 同时降低了通过蛋白质交叉反应性产生假阳性的可能性 在不同的套件中。ODA-CPL已经制定了第一个项目年的采购计划， 安装和开发方法，最终目标是授权分析师将其用于日常工作 监测人类食品，以补充国家抽样计划，以及 LFFM的人类食品测试分析跟踪。作为该过程的一部分，ODA-CPL将参加 能力测试计划作为其能力测试的一部分，并制定书面标准 纳入实验室质量计划的操作规程。实验室 将更新其实验室信息管理系统，以包括新的测试和成本 将对每个样品进行分析。ODA-CPL打算继续申请类似的 能力和能力发展项目，因为FDA继续为他们提供假设 ODA-CPL目前的人员、技术和设备以及工作流程与 项目

Increasing the Capability and Capacity of Microbiological and Chemical Testing to Support an Integrated Food Defense and Food Safety System Chemistry Discipline, Capability / Capacity Development Analytical Track Project Summary / Abstract The Ohio Department of Agriculture (ODA) Consumer Protection Laboratory (CPL) proposes incorporate an allergen screening method developed by the FDA into their laboratory as a routine screening method for human food products. The xMAP Food Allergen Detection Assay (xMAP FADA) kit innovates by working through a multiplex assay technology rather than more conventional ELISA technology; benefits include the ability to test for multiple allergens simultaneously and reduces the potential for a false positive through cross-reactivity of proteins across different kits. ODA-CPL has developed a plan for the first project year to purchase, install and develop the method with the end goal to authorize an analyst on its use for routine surveillance of human food products to supplement the state sampling program as well as LFFM’s human food testing analytical track. As part of the process, ODA-CPL will enroll in a proficiency testing scheme as part of its test of competency and develop written standard operating procedures for incorporation into the laboratory’s quality program. The laboratory will update its laboratory information management system to include the new test and a cost analysis per sample will be performed. ODA-CPL intends to continue applying for similar capability and capacity development projects as the FDA continues to offer them assuming ODA-CPL’s current personnel, technology and equipment and workflow is compatible with the project.